Drugs / MSB2311
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04272944 | Aug 2018 → Jan 2022 | — | Suzhou Transcenta Therapeutics Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03463473 | Apr 2018 → Jun 2020 | cancer | Suzhou Transcenta Therapeutics Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2021-05-20 | Suzhou Transcenta Therapeutics Co., Ltd. | Results Transcenta Announced the Results of the Phase I Clinical Study of PD-L1 Antibody MSB2311 with Advanced Solid Tumors and Hematological Malignancies transcenta.com ↗ |
| 2020-05-27 | Suzhou Transcenta Therapeutics Co., Ltd. | Results Transcenta Presents First Data from Phase 1 Study of pH-Dependent PDL1 Antibody MSB2311 in Patients with Pre-treated Advanced Solid Tumors and Select Hematological Malignancies transcenta.com ↗
Initial results suggest a favorable safety profile across all MSB2311 doses evaluated. |
| 2018-02-22 | Suzhou Transcenta Therapeutics Co., Ltd. | Regulatory MabSpace Biosciences Announces FDA Approval of IND for MSB2311, a Second Generation PD-L1 Antibody With pH Dependent Antigen Binding and Recycling Property transcenta.com ↗
MabSpace Biosciences announces on February 16th, 2018 FDA cleared Investigational New Drug (IND) for MSB2311, a humanized programmed death protein-ligand 1 (PD-L1) antibody for the treatment of patients with locally advanced/metastatic solid tumors. |
| 2017-10-25 | Suzhou Transcenta Therapeutics Co., Ltd. | Regulatory MabSpace Biosciences Submits Investigational New Drug Application for its Second Generation PD-L1 Antibody With pH-Dependent Antigen Binding Property transcenta.com ↗
MabSpace Biosciences Co., Ltd., today announced it has filed an IND application to CFDA on September 12th, 2017 for MSB2311, a second-generation PD-L1 antibody with pH-dependent antigen binding property. |
All press releases naming this drug 6 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSB2311 | “MSB2311, a humanized anti-PD-L1 monoclonal antibody” NCT04272944 ↗ |
| Modality | Monoclonal antibody | “MSB2311, a humanized anti-PD-L1 monoclonal antibody” NCT03463473 ↗ |
| Route | Intravenous | “MSB2311 will be administered as an IV infusion” NCT03463473 ↗ |